$CYCC
Cyclacel Pharmaceuticals, Inc.

2024 Q2 Form 10-Q Financial Statement

#000155837024008159 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $4.000K $29.00K
YoY Change -98.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.625M $1.582M
YoY Change 3.17% -3.83%
% of Gross Profit
Research & Development $2.023M $2.802M
YoY Change -57.2% -50.62%
% of Gross Profit
Depreciation & Amortization $2.000K $2.000K
YoY Change -75.0% -75.0%
% of Gross Profit
Operating Expenses $3.648M $4.384M
YoY Change -42.11% -40.1%
Operating Profit -$3.644M -$4.355M
YoY Change -38.54% -40.5%
Interest Expense -$25.00K $3.000K
YoY Change -2600.0% -89.66%
% of Operating Profit
Other Income/Expense, Net -$25.00K $55.00K
YoY Change -76.19% -71.79%
Pretax Income -$3.669M -$4.300M
YoY Change -39.19% -39.64%
Income Tax -$412.0K -$1.354M
% Of Pretax Income
Net Earnings -$3.257M -$2.946M
YoY Change -40.22% -49.24%
Net Earnings / Revenue -81425.0% -10158.62%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.72 -$2.27
COMMON SHARES
Basic Shares Outstanding 1.463M 1.318M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.000M $2.798M
YoY Change -40.97% -75.53%
Cash & Equivalents $6.000M $2.800M
Short-Term Investments
Other Short-Term Assets $300.0K $365.0K
YoY Change -86.28% -38.66%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.707M $4.835M
YoY Change -49.61% -74.52%
LONG-TERM ASSETS
Property, Plant & Equipment $5.000K $7.000K
YoY Change -79.17% -77.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $413.0K $1.244M
YoY Change -58.7% -57.34%
Total Long-Term Assets $483.0K $1.330M
YoY Change -57.93% -56.9%
TOTAL ASSETS
Total Short-Term Assets $7.707M $4.835M
Total Long-Term Assets $483.0K $1.330M
Total Assets $8.190M $6.165M
YoY Change -50.19% -72.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.741M $5.200M
YoY Change 118.58% 107.25%
Accrued Expenses $2.445M $3.150M
YoY Change -46.58% -34.77%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.186M $8.350M
YoY Change 6.52% 13.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.000K $21.00K
YoY Change -92.42% -73.75%
Total Long-Term Liabilities $5.000K $21.00K
YoY Change -92.42% -73.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.186M $8.350M
Total Long-Term Liabilities $5.000K $21.00K
Total Liabilities $7.191M $8.371M
YoY Change 5.56% 12.85%
SHAREHOLDERS EQUITY
Retained Earnings -$434.5M -$431.2M
YoY Change 4.09% 4.68%
Common Stock $2.000K $1.000K
YoY Change -77.78% -88.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $999.0K -$2.206M
YoY Change
Total Liabilities & Shareholders Equity $8.190M $6.165M
YoY Change -50.19% -72.05%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$3.257M -$2.946M
YoY Change -40.22% -49.24%
Depreciation, Depletion And Amortization $2.000K $2.000K
YoY Change -75.0% -75.0%
Cash From Operating Activities -$3.084M -$483.0K
YoY Change 136.32% -92.96%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.289M -79.00K
YoY Change -12431.37% 58.0%
NET CHANGE
Cash From Operating Activities -3.084M -483.0K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 6.289M -79.00K
Net Change In Cash 3.205M -580.0K
YoY Change -336.36% -91.61%
FREE CASH FLOW
Cash From Operating Activities -$3.084M -$483.0K
Capital Expenditures $0.00 $0.00
Free Cash Flow -$3.084M -$483.0K
YoY Change 136.32% -92.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Cyclacel Pharmaceuticals, Inc.
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1318259
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001130166
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1058892
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
000-50626
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1707622
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Connell Drive
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1500
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Berkeley Heights
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07922
CY2024Q1 dei City Area Code
CityAreaCode
908
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
517-7330
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1463259
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2798000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3378000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2037000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4066000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
4835000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7444000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
79000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
93000
CY2024Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1244000
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1259000
CY2024Q1 us-gaap Assets
Assets
6165000
CY2023Q4 us-gaap Assets
Assets
8805000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5200000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3543000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3150000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4618000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
8350000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8161000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37000
CY2024Q1 us-gaap Liabilities
Liabilities
8371000
CY2023Q4 us-gaap Liabilities
Liabilities
8198000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1318259
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1058892
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
429919000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
429796000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-898000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-908000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-431228000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-428282000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2206000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
607000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6165000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8805000
CY2024Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
29000
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2802000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5674000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1582000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1645000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
4384000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
7319000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4355000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7319000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-87000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
116000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
52000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
166000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
55000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
195000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4300000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7124000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1354000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1320000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2946000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5804000
CY2024Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0
CY2023Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
50000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2946000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5854000
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.27
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.00
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2946000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5804000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2140000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5171000
CY2024Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-2130000
CY2023Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
5263000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2936000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5712000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15939000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
401000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
50000
CY2023Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
5263000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5171000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5804000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
10578000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
607000
CY2024Q1 cycc Stock Issued During Period Value Upon Conversion Of Pre Funded Warrants In Underwritten Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueUponConversionOfPreFundedWarrantsInUnderwrittenOfferingNetOfIssuanceCosts
-80000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
203000
CY2024Q1 cycc Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax
OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax
-2130000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2140000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2946000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2206000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-2946000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-5804000
CY2024Q1 us-gaap Depreciation
Depreciation
2000
CY2023Q1 us-gaap Depreciation
Depreciation
8000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
203000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
401000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-16000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-26000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2020000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1234000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
254000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-206000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-483000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6861000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
79000
CY2023Q1 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
50000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-79000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-50000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-18000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-580000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6910000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3378000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18345000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2798000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11435000
CY2024Q1 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
1000
CY2023Q1 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
116000
CY2024Q1 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
2925000
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
CY2023Q1 cycc Accrual Of Preferred Stock Dividends
AccrualOfPreferredStockDividends
50000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2800000
CY2024Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2023Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2024Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2024Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
29000
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
829492
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
428551
CY2024Q1 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
1343000
CY2023Q4 us-gaap Deferred Income Taxes And Other Tax Receivable Current
DeferredIncomeTaxesAndOtherTaxReceivableCurrent
2933000
CY2024Q1 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
329000
CY2023Q4 cycc Prepayments And Value Added Tax Receivable Current
PrepaymentsAndValueAddedTaxReceivableCurrent
792000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
365000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
341000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2037000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4066000
CY2024Q1 cycc Deposits Held By Related Party
DepositsHeldByRelatedParty
1200000
CY2024Q1 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
2531000
CY2023Q4 cycc Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3668000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
323000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
570000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
296000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
380000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3150000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4618000
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
19039
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
17949
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
17949
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
19037
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
17634
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
17634
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
49000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
38000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
87000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
8000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
79000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
203000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
401000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
700000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M6D
CY2024Q1 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.06
CY2024Q1 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.06
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-008159-index-headers.html Edgar Link pending
0001558370-24-008159-index.html Edgar Link pending
0001558370-24-008159.txt Edgar Link pending
0001558370-24-008159-xbrl.zip Edgar Link pending
cycc-20240331.xsd Edgar Link pending
cycc-20240331x10q.htm Edgar Link pending
cycc-20240331x10q001.jpg Edgar Link pending
cycc-20240331x10q002.jpg Edgar Link pending
cycc-20240331xex31d1.htm Edgar Link pending
cycc-20240331xex31d2.htm Edgar Link pending
cycc-20240331xex32d1.htm Edgar Link pending
cycc-20240331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
cycc-20240331_def.xml Edgar Link unprocessable
cycc-20240331_lab.xml Edgar Link unprocessable
cycc-20240331_pre.xml Edgar Link unprocessable
cycc-20240331x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cycc-20240331_cal.xml Edgar Link unprocessable